PBRM1 and neoplasm: For example, Gulati et al. aim to evaluate validated biomarkers that are being utilized to guide treatment choices and help identify pathways of resistance in other tumor types, and do this by organizing their paper by biomarker (PD-L1, tumor mutational burden, VHL, PBRM1, BAP1, SETD2, a few genomic signatures) [13].